Free preview. Sign up free to see the team, full portfolio, ownership chain, and shareholding history.
Sign up freePricing

Oxford Science Enterprises Plc investment portfolio

Oxford Science Enterprises Plc has made numerous investments in companies such as Refeyn, Opsydia, and Nucleome Therapeutics within the Biotech sector.

university
Portfolio
33
Team
0

Portfolio (33)

CompanySectorSourceLast confirmed on
Alethio Therapeutics Limited
Alethio Therapeutics Limited is a biotechnology company that develops disease-modifying antibody-drug conjugates (ADCs) for the treatment of myeloproliferative neoplasms (MPNs), a group of chronic blood cancers. The company utilizes its proprietary ARTEMIS discovery engine to identify and validate novel targets for precision therapies, including its lead programs AT-01 and AT-02, which are designed to selectively eliminate disease-driving cells.
Healthcare & Life SciencesConfirmed2025-07-12
Cora Biosciences LimitedHealthcare & Life SciencesConfirmed—

Sign up to see the full portfolio

+31 more companies

Sign up

Shareholding changes (21)

Oxford Science Enterprises Plc's positions across portfolio companies
2026
  • 04-26ChangedRefeyn Ltd
    • ORDINARY 5,161,000 → 0
    • SERIES A1 3,114,268 → 0
    • SERIES B 5,034,339 → 0
    • ELECTRONICALLY FILED DOCUMENT FOR COMPANY NUMBER: 11333643 0 SERIES A1 0 → 3,114,268
  • 03-17AddedPorpoise Power Limited
    • PREFERRED 0 → 2

Sign up free to see when this investor has bought or sold shares.

+19 more changes

Sign up

Articles (4)